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This study was carried out to determine the antibody responses and protective capacity of an 
inactivated recombinant vaccine expressing the cell wall surface anchor family protein of 
Streptococcus agalactiae following oral vaccination against streptococcosis in tilapia. Tilapia 
were vaccinated orally with 106 CFU/mL of the recombinant vaccine incorporated in feed 
(feed-based recombinant vaccine) (vaccinated group or Group 1), 106 CFU/mL of pET-32 
Ek/LIC vector without cell wall surface anchor family protein (control group or Group 2), 
106 CFU/mL of formalin-killed cells of S. agalactiae vaccine incorporated in feed was also 
prepared (feed-based vaccine) (vaccinated group or Group 3), and unvaccinated control group 
or Group 4 (fed with commercial pellets). During the course of study, serum, mucus and gut 
lavage fluid were collected to evaluate the antibody levels via enzyme-linked immunosorbent 
assay (ELISA). The results showed that tilapia immunized with the feed-based recombinant 
vaccine developed a strong and significantly (P < 0.05) higher IgM antibody response in 
serum, mucus and gut lavage fluid samples compared to groups 2, 3 and 4. Following heat 
intervenes and intraperitoneal challenge, the rate of survivors (RPS) was 70% for the 
vaccinated group, and 0% for the rest of the groups. Therefore, the study revealed that the 
feed-based recombinant vaccine significantly provides high protection against high dose 
challenge in heat stress environment and enhances the production of the mucosal and 
humoral immunity. 
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